

CO.DON AG again a prizewinner at GERMAN STEVIE AWARDS

Berlin / Teltow, 9 April 2018 – CO.DON AG is again a prizewinner at the German Stevie Awards 2018. Nominated under the title of “New era for cartilage repair”, the company won the “Silver Stevie Award” in the category “Company of the Year – Healthcare Products & Services”. In their assessments the jury members particularly emphasised the innovative character and medical significance of the product. They praised the company’s transformation from a research-driven, biotechnology operation to a biopharmaceutical product-driven business.

The German Stevie Awards are a prestigious business competition for companies in Germany. Outstanding performance is rewarded in more than 80 different categories. Some 50 managers from across Germany, pooled in expert juries, decide who wins one of the sought-after Stevies. They reviewed over 400 applications, singled out the most innovative solutions and finally chose the winners of the Gold, Silver and Bronze Stevie Awards.

Ralf Jakobs, Executive Board of CO.DON AG: “This award is for the entire CO.DON team, and my thanks go to everyone on the staff. A “New era for cartilage repair” is also the beginning of a new era for CO.DON. Our product is currently the only available cell-based pharmaceutical for the treatment of cartilage damage in the knee joint that is authorised for distribution across Europe. In order to meet forecast demand we are building another production facility in Leipzig – when it is finished it will be one of the world’s largest and most modern facilities for the industrial production of human cells. This will enable us to keep fulfilling our goal of reliably supplying our users with the highest quality cell therapy products.”

CO.DON AG develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage defects in the knee following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). The treatment has been used in over 200 clinics to treat more than 12,000 patients. In July 2017 the company received EU marketing authorisation for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from: www.codon.eu

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Corporate communications / IR / PR

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de